Allogeneic stem cell transplantation for metastatic renal cell cancer (RCC)

Research output: Contribution to journalArticle

Abstract

A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.

Original languageEnglish
Pages (from-to)347-349
Number of pages3
JournalJournal of Cancer
Volume2
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Stem Cell Transplantation
Renal Cell Carcinoma
Transplants
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Cytokines
Survival
Mortality
Neoplasms
Therapeutics

Keywords

  • Advanced renal cell cancer
  • Allogeneic hematopoietic stem cell transplantation
  • Graft-versus-tumor

ASJC Scopus subject areas

  • Oncology

Cite this

Allogeneic stem cell transplantation for metastatic renal cell cancer (RCC). / Bregni, Marco; Ciceri, Fabio; Peccatori, Jacopo.

In: Journal of Cancer, Vol. 2, No. 1, 2011, p. 347-349.

Research output: Contribution to journalArticle

@article{ab9aa439847d470db323a4f1d516c359,
title = "Allogeneic stem cell transplantation for metastatic renal cell cancer (RCC)",
abstract = "A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.",
keywords = "Advanced renal cell cancer, Allogeneic hematopoietic stem cell transplantation, Graft-versus-tumor",
author = "Marco Bregni and Fabio Ciceri and Jacopo Peccatori",
year = "2011",
doi = "10.7150/jca.2.347",
language = "English",
volume = "2",
pages = "347--349",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "1",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for metastatic renal cell cancer (RCC)

AU - Bregni, Marco

AU - Ciceri, Fabio

AU - Peccatori, Jacopo

PY - 2011

Y1 - 2011

N2 - A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.

AB - A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.

KW - Advanced renal cell cancer

KW - Allogeneic hematopoietic stem cell transplantation

KW - Graft-versus-tumor

UR - http://www.scopus.com/inward/record.url?scp=84876022702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876022702&partnerID=8YFLogxK

U2 - 10.7150/jca.2.347

DO - 10.7150/jca.2.347

M3 - Article

AN - SCOPUS:84876022702

VL - 2

SP - 347

EP - 349

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 1

ER -